MAINZ BIOMED
Mainz BioMed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. Mainz Bio is Specializing in the early detection of cancer with it's flagship product COloAlert.
MAINZ BIOMED
Industry:
Biotechnology
Founded:
2021-01-01
Address:
Mainz, Rheinland-Pfalz, Germany
Country:
Germany
Website Url:
http://www.mainzbiomed.com
Total Employee:
11+
Status:
Active
Contact:
+49 (0) 6131 / 55428-60
Email Addresses:
[email protected]
Total Funding:
22.5 M USD
Technology used in webpage:
Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Person Schema COVID-19
Similar Organizations
Dxcover
The Future of Cancer Diagnostics
GNA Biosolutions
GNA Biosolutions is a private molecular diagnostics company.
Molbio Diagnostics
Molbio Diagnostics is a molecular diagnostics manufacturer.
NuProbe
NuProbe is a cutting-edge genomics and molecular diagnostics company.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Sense Biodetection
Sense Biodetection Limited is a molecular diagnostics company .
Singleron Biotechnologies
Singleron Biotechnologies is an innovative molecular diagnostic company.
CareDx
CareDx is a novel molecular diagnostics company.
Current Employees Featured
Founder
Stock Details
Key Employee Changes
Official Site Inspections
http://www.mainzbiomed.com Semrush global rank: 9.08 M Semrush visits lastest month: 218
Unable to get host informations!!!
More informations about "Mainz Biomed"
Home - Mainz Biomed
Nov 12, 2024 · We develop innovative products that quickly and reliably identify the early onset of several leading deadly conditions – such as colorectal (“CRC”) and pancreatic cancer. Our …See details»
Our Company - Mainz Biomed
Mainz BioMed (NASDAQ: MYNZ) develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. Mainz Biomed (NASDAQ: MYNZ) is located just west of Frankfurt in a world-renowned community for …See details»
Group - Mainz Biomed
We develop innovative products that quickly and reliably identify the early onset of several leading deadly conditions – such as colorectal (“CRC”) and pancreatic cancer. To meet this demand, …See details»
Mainz Biomed - Crunchbase Company Profile & Funding
Mainz BioMed primarily operates as a molecular genetic diagnostics company. It develops market-ready molecular genetic diagnostic solutions for life-threatening conditions.See details»
The Journey of Mainz BioMed: From Start-up to a …
Mar 21, 2024 · Mainz BioMed (https://mainzbiomed.com/), a revolutionary biotech company founded in Mainz, Germany, stands at the forefront of cancer diagnostic innovation, particularly in the battle against...See details»
Mainz Biomed - LinkedIn
We develop innovative products that quickly and easily identify the early onset of several leading deadly conditions including colorectal and pancreatic cancers. Visit our website...See details»
Mainz Biomed and Thermo Fisher Scientific Sign a - GlobeNewswire
Nov 12, 2024 · Mainz Biomed’s flagship non-invasive test not only targets the early detection of colorectal cancer but also focuses on precancerous lesions, particularly advanced adenomas, …See details»
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes …
Oct 1, 2024 · Mainz Biomed's flagship non-invasive test not only targets the early detection of colorectal cancer but also focuses on precancerous lesions, particularly advanced adenomas, …See details»
OUR BUSINESS - Mainz Biomed
Mainz BioMed is currently developing proprietary genetic testing methods for pancreatic cancer. Fighting what could soon become the world’s second most deadly cancer.* Convenient stool …See details»
Mainz Biomed Announces Submission for FDA Breakthrough
Jul 9, 2024 · On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in …See details»
Mainz Biomed Partners with Liquid Biosciences to Harness the …
Nov 9, 2023 · BERKELEY, Calif. and MAINZ, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular …See details»
Mainz Biomed Announces Pricing of $5.0 million Registered Direct …
Nov 13, 2023 · BERKELEY, Calif. and MAINZ, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (Nasdaq: MYNZ) (“Mainz Biomed” or the “Company”), a molecular …See details»
Mainz Biomed Presented Industry Leading Results of its Pooled …
Jun 3, 2024 · Results from pooled study represents the third consecutive confirmation of the consistently good performance of Mainz Biomed’s mRNA biomarkers to detect CRC and …See details»
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration ...
Nov 12, 2024 · BERKELEY, US and MAINZ, Germany – November 12, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic …See details»
Mainz Biomed Announces the Closing of its $25.8 Million
Jan 28, 2022 · Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non …See details»
Mainz Biomed Reports Positive Topline Results from Pooled Study ...
Apr 25, 2024 · The topline results confirm the positive efficacy results previously reported with a sensitivity for colorectal cancer of 92% with a specificity of 90% and a sensitivity for advanced …See details»
Mainz Biomed N.V. (MYNZ) Stock Price, Quote & News - Stock …
1 day ago · Get a real-time Mainz Biomed N.V. (MYNZ) stock price quote with breaking news, financials, statistics, charts and more.See details»
Investors - Mainz Biomed
Oct 28, 2021 · Founded in 2008 and located in Mainz, Germany – a world-renowned community for advanced DNA and pharmaceutical research. Mainz Biomed is led by a seasoned …See details»
Mainz BioMed | Mainz - Facebook
Mainz BioMed, Mainz. 520 likes · 8 talking about this. Mainz BioMed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. https://mainzbiomed.com/See details»
Mainz Biomed Reports Mid-Year 2024 Financial Results and …
Oct 21, 2024 · BERKELEY, US – MAINZ, Germany – October 21, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic …See details»